The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure

Expert Opinion on Investigational Drugs

Volumn 13, Issue 3, 2004, Pages 245-253

  McKelvie, Robert S ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Angiotensin II receptor blocker; Clinical trials; Heart failure; Heart failure therapy

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; INOTROPIC AGENT; IRBESARTAN; LOSARTAN; NEUROHORMONE; PLACEBO; RENIN; SPIRONOLACTONE; VALSARTAN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BIOSYNTHESIS; CLINICAL STUDY; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HEART FAILURE; HEART FUNCTION; HORMONE ACTION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MEDICAL LITERATURE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPTOMATOLOGY;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CLINICAL TRIALS; DIASTOLE; HEART; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; TREATMENT OUTCOME;

EID: 1542393518     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.3.245     Document Type: Review

References (45)

1. LEVINE TB, FRANCIS GS, GOLDSMITH SR et al.: Activity of the sympathetic nervous system and reninangiotensin system and their relationship to hemodynamic abnormalities in congestive heart failure. Am. J. Cardiol, (1982) 49:1659-1666.
2. FRANCIS GS, COHN JN, JOHNSON G et al.: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation (1993) 87:40-48.
3. WEBER KT, SUN Y, KATAWA LC: Wound healing following myocardial infarction. Clin. Cardiol. (1996) 19:447-455.
4. CARSON PE: Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am. Heart J. (2000) 140:361-366.
5. BENEDICT CR, FRANCIS GS, JOHNSTONE DE et al.: For the SOLVD Investigators. Effect of long term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am. J. Cardiol. (1995) 75:1151-1157.
6. BRUNNER-LA ROCCA HP, VADDADI G, ESLER MD: Recent insight into therapy of congestive heart failure: Focus on ACE inhibition and angiotensin-II antagonism. J. Am. Coll. Cardiol. (1999) 33(5):1163-1173.
7. ROIG E, PEREZ-VILLA F, MORALES M et al.: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur. Heart J. (2000) 21:53-57.
8. PITT B: Escape of aldosterone production patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardovasc. Drugs Ther. (1995) 9:145-149.
9. LEE WH, PACKER M: Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation (1986) 73:257-267.
10. STRUTHERS AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur. Heart J. (1995) 16(Suppl. N):103-106.
11. URATA H, KINOSHITA A, MISONO KS et al.: Identification of a highly specific chymase as the major angiotensin II forming enzyme in the human heart. J. Biol. Chem. (1990) 265:22348-22357.
12. LIU YH, YANG XP, SHAROV VG et al.: Effects of angiotensin converting enzyme inhibitors and angiotensin II Type I receptor antagonists in rats with heart failure. Role of kinins and angiotensin II Type II receptors. J. Clin. Invest. (1997) 90:1926-1935.
13. RIEGGER GA, BOUZO H, PETR P et al.: For the STRETCH investigators: Improvement of exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation (1999) 100:2224-2230.
14. GRANGER CB, ERTL G, KUCH J et al.: For the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) investigators randomized trial of candesartan cilexetil in the treatment of congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart J. (2000) 139:609-617.
15. MATSUMORI A. On behalf of the assessment of response to candesartan in heart failure in Japan (ARCH-J) study investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur. J. Heart Fail. (2003) 5:669-677.
16. CROZIER I, IKRAM H, ARVAN N et al.: For the Losartan Hemodynamic Study Group. Losartan in heart failure: Hemodynamic effects and tolerability. Circulation (1995) 91:691-697.
17. HAVRANEK EP, THOMAS I, SMITH WB et al.: For the Irbesartan Heart Failure Group. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J. Am. Coll. Cardiol. (1999) 33:1174-1181.
18. MAZAYEV VP, FOMINA IG, KAZAKOV EN et al.: Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int. J. Cardiol. (1998) 65:239-246.
19. FLATHER M, YUSUF S, KOBER L et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: A systematic overview of data from individual patients. ACE Inhibitor Myocardial Collaborative Group. Lancet (2000) 355:1575-1581.
20. LANG RM, ELKAYAM U, YELLEN LG et al.: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J. Am. Coll. Cardiol. (1997) 30:983-1017.
21. DICKSTEIN K, CHANG P, WILLENHEIMER R et al.: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J. Am. Coll. Cardiol. (1995) 26:438-445.
22. McKELVIE RS, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: The RESOLVD Pilot Study Investigators. Circulation (1999) 100:1056-1064.
23. PITT B, SEGAL R, MARTINEZ FA et al.: On behalf of the ELITE study investigators. Lancet (1997) 349:747-752.
24. McDONALD KM, MOCK J, D'ALOIA A et al.: Bradykinin antagonism inhibits the anti-growth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation (1995) 91:2043-2048.
25. TONKON M, AWAN N, NIAZI I et al.: A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Int. J. Clin. Pract. (2000) 54:11-18.
26. 1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects. Am. Heart J. (2001) 141:800-807.
27. BARUCH L, ANAND I, COHEN IS et al.: For the Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short-term and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation (1999) 99:2658-2664.
28. HAMROFF G, KATZ SD, MANCINI D et al.: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 99:990-992.
29. PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial - The Losartan Heart Failure Survival Study (ELITE II). Lancet (2000) 355:1582-1587.
30. COHN JN, TOGNONI G: For the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345:1667-1675.
31. DICKSTEIN K, KJEKSHUS J, OPTIMAAL STEERING COMMITTEE: For the OPTIMAAL Study Group. Effects of Losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infraction: The OPTIMAAL randomized trial. Lancet (2002) 360:752-760.
32. SWEDBERG K, PFEFFER M, GRANGER C et al.: Candesartan in heart failure. Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J. Card. Fail. (1999) 5(3):276-282.
33. PFEFFER MA, MCMURRAY J, VELAZQUES EJ et al.: For the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349:1893-1906.
34. PFEFFER MA, SWEDBERG K, GRANGER CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM - Overall programme. Lancet (2003) 362:759-766.
35. McMURRAY JJV, STERGREN J, SWEDBERG K et al.: For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: The CHARM - Added trial. Lancet (2003) 362:767-771.
36. GRANGER CB, McMURRAY JJV, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet (2003) 362:772-776.
37. YUSUF S, PFEFFER MA, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved trial. Lancet (2003) 362:777-781.
38. McKELVIE RS, ROULEAU J-L, WHITE M et al.: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodeling in patients with congestive heart failure. Eur. Heart J. (2003) 24:1727-1734.
39. 1 receptor blockers? Arch. Intern. Med. (2003) 163:240-241.
40. TRESCH DD, McGOUGH MF: Heart failure with normal systolic function: A common disorder in older people. J. Am. Geriatr. Soc. (1995) 43:1035-1042.
41. McKELVIE RS, BENEDICT CR, YUSUF S: Prevention of congestive heart failure and treatment of asymptomatic left ventricular dysfunction. In: Evidence-Based Cardiology. (2nd Ed.). S Yusuf, JA Cairns, AJ Cam, EL Fallen, BJ Gersh (Eds), British Medical Journal Books (2003):643-658.
42. THE TASK FORCE OF THE WORKING GROUP ON HEART FAILURE OF THE EUROPEAN SOCIETY OF CARDIOLOGY. The treatment of heart failure. Eur. Heart J. (1997) 18:736-753.
43. TENDERA M: Ageing anT heart failure: the place of ACE inhibitors in heart failure with preserved systolic function. Eur. Heart J. (2000) 2:I8-I14.
44. YUSUF, S, GERSTEIN H, HOOGWERF B et al.: Ramipril and the development of diabetes. JAMA (2001) 286:1882-1885.
45. DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: For the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for End point reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet (2002) 359:995-1003